Fig. 6

Aberrant miR-455-3p contributes to the progression of various cancers. a Analysis of TCGA datasets indicating that miR-455-3p is aberrantly upregulated in subsets of primary tumors, including gastric, lung, bladder, breast, cervical, head and neck, kidney, thyroid, and uterine cancers. b Kaplan–Meier analysis of overall survival for the indicated cancer patients with low or high miR-455-3p expression. c RIP analysis of the association between miR-455-3p and the 3’UTR of the indicated genes. GAPDH served as a negative control. d Relative luciferase activities of the TOP/FOP reporter or TGF-β reporter activity in the indicated cells. e Representative images of CDDP-treated tumor-bearing mice (left panel) and weight of xenografts (right panel) intratumorally injected with antagomir control or antagomirR-455-3p. f Hypothetical model illustrating that aberrant expression of miR-455-3p activates multiple cancer stem cell-associated signaling pathways, leading to cancer progression, chemotherapy failure, and poor clinical outcomes. Each bar represents the mean ± SD of three independent experiments. *P < 0.05